A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese
participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic
anticancer therapy.